A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies

Journal of Neurochemistry

Volumn 137, Issue 5, 2016, Pages 687-700

  Marciani, Dante J ^a  

^a Qantu Therapeutics Inc   (United States)

Author keywords

Alzheimer's vaccines; amyloid beta; anti inflammatory adjuvants; conjugated vaccines; DNA vaccines; tau protein

Indexed keywords

ABVAC 40; AD 02; ADUCANUMAB; ALZHEIMER DISEASE VACCINE; AMYLOID BETA OLIGOMER; AMYLOID BETA PROTEIN; DNA VACCINE; EPITOPE; FUCOSE; OLIGOMER; PHOSPHORYLCHOLINE; SOLANEZUMAB; TAU PROTEIN; UB 311; UNCLASSIFIED DRUG; V 950; VANUTIDE CRIDIFICAR;

ALZHEIMER DISEASE; ANTIBODY AFFINITY; ANTIBODY RESPONSE; CARRIER INDUCED EPITOPE SPECIFIC SUPPRESSION; CELLULAR IMMUNITY; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RETROSPECTIVE STUDY; REVIEW; TRANSGENIC MOUSE; VACCINATION; ANIMAL; DRUG DEVELOPMENT; IMMUNOLOGY; PROCEDURES; TRENDS;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; DRUG DISCOVERY; HUMANS; RETROSPECTIVE STUDIES; VACCINATION;

EID: 84963682608     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13608     Document Type: Review

References (115)

1. Agadjanyan M. G., Petrovsky N., and, Ghochikya A., (2015) A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement. 10, 1246-1259.
2. Akira S., (2011) Innate immunity and adjuvants. Philos. Trans. R. Soc. B 366, 2748-2755.
3. Arai H., Suzuki H., and, Yoshiyama T., (2015) Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies. Curr. Alzheimer Res. 12, 242-254.
4. Asakura Y., Liu L.-J., Shono N., Hinkula J., Kjerrström A., Aoki I., Okuda K., Wahren B., and, Fukushima J., (2000) Th1-biased immune responses induced by DNA-based immunizations are mediated via action on professional antigen-presenting cells to up-regulate IL-12 production. Clin. Exp. Immunol. 119, 130-139.
5. Avila J., Lucas J. J., Pérez M., and, Hernández F., (2004) Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84, 361-384.
6. Balakrishnan K., Upadhaya A. R., Steinmetz J., et al,. (2015) Impact of amyloid β aggregate maturation on antibody treatment on APP23 mice. Acta Neuropathol. Commun. 3, 41.
7. Bergmann-Leitner E. S., and, Leitner W. W., (2014) Adjuvants in the driver's seat: how magnitude, type, fine specificity and longevity of immune responses are driven by distinct classes of immune potentiators. Vaccines 2, 252-296.
8. Bode C., Zhao G., Steinhagen F., Kinjo T., and, Klinman D. M., (2011) CpG DNA as a vaccine adjuvant. Expert Rev. Vaccin. 10, 499-511.
9. Boeckler C., Frisch B., Muller S., and, Schuber F., (1996) Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes. J. Immunol. Methods 191, 1-10.
10. Britschgi M., Olin C. E., Johns H. T., et al,. (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc. Natl Acad. Sci. USA 106, 12145-12150.
11. Brouillette J., (2014) The effects of soluble Aβ oligomers on neurodegeneration in Alzheimer's disease. Curr. Pharm. Des. 20, 2506-2519.
12. 40 in vivo. Acta Neuropathol. 130, 35-47.
13. Burns T. C., Li M. D., Mehta S., Awad A. J., and, Morgan A. A., (2015) Mouse models rarely mimic the transcriptome of human neurodegenerative diseases: a systematic bioinformatics-based critique of preclinical models. Eur. J. Pharmacol. 759, 101-117.
14. Busche M. A., Grienberger C., Keskin A. D., Song B., Neumann U., Staufenbiel M., Förstl H., and, Konnerth A., (2015) Decreased amyloid-b and increased neuronal hyperactivity in Alzheimer's models. Nat. Neurosci. 18, 1725-1727.
15. Carrera I., Etcheverría I., Fernández-Novoa L., Lombardi V. R. M., Lakshmana M. K., Cacabelos R., and, Vigo C., (2015) A comparative evaluation of a novel vaccine in APP/PS1 mouse models of Alzheimer's disease. Biomed. Res. Int. 2015, 807146. doi: 10.1155/2015/807146.
16. Castillo-Carranza D. L., Sengupta U., Guerrero-Muñoz M. J., et al,. (2014) Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 34, 4260-4272.
17. Cavanaugh S. E., Pippin J. J., and, Barnard N. D., (2014) Animal models of Alzheimer disease: historical pitfalls and a path forward. ALTEX 31, 279-302.
18. Chackerian B., Rangel M., Hunter Z., and, Peabody D. S., (2006) Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-β without concomitant T cell responses. Vaccine 24, 6321-6331.
19. Coban C., Kobiyama K., Jounai N., Tozuka M., and, Ishii K. J., (2013) DNA vaccines: a simple DNA sensing matter. Hum. Vaccin. Immunother. 9, 2216-2221.
20. Davtyan H., Mkrtichyan M., Movsesyan N., Petrushina I., Mamikonyan G., Cribbs D. H., Agadjanyan M. G., and, Ghochikyan A., (2010) DNA prime-protein boost increased the titer, avidity and persistence of anti-Ab antibodies in wild-type mice. Gene Ther. 17, 261-271. doi: 10.1038/gt.2009.140. Epub 2009 Oct 29.
21. Davtyan H., Ghochikyan A., Hovakimyan A., Davtyan A., Cadagan R., Marleau A. M., Albrecht R. A., García-Sastre A., and, Agadjanyan M. G., (2014) A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory. J. Neuroimmunol. 277, 77-84.
22. De Genst E., Messer A., and, Dobson C. M., (2014) Antibodies and protein misfolding: from structural research tools to therapeutic strategies. Biochim. Biophys. Acta 1844, 1907-1919.
23. Deng J., Hou H., Giunta B., Mori T., Wang Y.-J., Fernandez F., Weggen S., Araki W., Obregon D., and, Tan J., (2012) Autoreactive Aβ-antibodies promote APP β-secretase processing. J. Neurochem. 120, 732-740.
24. Dodel R., Balakrishnan K., Keyvani K., et al,. (2011) Naturally occurring autoantibodies against b-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J. Neurosci. 31, 5847-5854.
25. Eisen H. N., (2014) Affinity enhancement of antibodies: how low-affinity antibodies produced early in immune responses are followed by high-affinity antibodies later and in memory B-cell responses. Cancer Immunol. Res. 2, 381-392.
26. Ejima D., Tsumoto K., Fukada H., Yumioka R., Nagase K., Arakawa T., and, Philo J. S., (2007) Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies. Proteins 66, 954-962.
27. Elsawa S. F., Rodeberg D. A., and, Celis E., (2004) T-cell epitope peptide vaccines. Expert Rev. Vaccin. 3, 563-575.
28. Farlow M. R., Andreasen N., Riviere M. E., Vostiar I., Vitaliti A., Sovago J., Caputo A., Winblad B., and, Graf A., (2015) Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res. Ther. 7, 23. doi: 10.1186/s13195-015-0108-3.
29. Ferrer I., Rovira M. B., Sanchez Guerra M. L., Rey M. J., and, Costa-Jussa F., (2004) Neuropathology and pathogenesis of encephalitis following amyloid β immunization in Alzheimer's disease. Brain Pathol. 14, 11-20.
30. Fillit H., Hess G., Hill J., Bonnet P., and, Toso C., (2009) IV immunoglobulin is associated with a reduced risk of Alzheimer's disease and related disorders. Neurology 73, 180-185.
31. Fu H. J., Liu B., Frost J. L., and, Lemere C. A., (2010) Amyloid-β immunotherapy for Alzheimer's disease. CNS Neurol. Disord. Drug Targets 9, 197-206.
32. Furlan R., Brambilla E., Sanvito F., Roccatagliata L., Olivieri S., Bergami A., Pluchino F., Uccelli A., Comi G., and, Martino G., (2003) Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 126, 285-291.
33. Gherardi R. K., Eidi H., Crépeaux G., Authier F. J., and, Cadusseau J., (2015) Biopersistence and brain translocation of aluminum adjuvants in vaccines. Front. Neurol. 6, 4. doi: 10.3389/fneur.2015.00004.
34. Gold M., Mengel D., Röskam S., Dodel R., and, Bach J. P., (2013) Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia. J. Neuroinflammation 10, 5.
35. Goronzy J. J., and, Weyand C. M., (2013) Understanding immune senescence to improve vaccine responses. Nat. Immunol. 14, 428-436. doi: 10.1038/ni.2588.
36. del Guercio M. F., Alexander J., Kubo R. T., et al,. (1997) Potent immunogenic short linear peptide constructs composed of B cell epitopes and PAN DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 15, 441-448.
37. Haynes L., Eaton S. M., Burns E. M., Ricon M., and, Swain S. L., (2004) Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J. Immunol. 172, 5194-5199. doi: 10.4049/jimmunol.172.9.5194.
38. Head E., (2013) A canine model of human aging and Alzheimer's disease. Biochim. Biophys. Acta 1832, 1384-1389.
39. Heneka M. T., Carson M. J., Khoury J. E., et al,. (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14, 388-405.
40. Hoogerhout P., Kamphuis W., Brugghe H. F., et al,. (2011) A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques. PLoS ONE 6, e19110. doi: 10.1371/journal.pone.0019110.
41. Jeffrey S., (2015) More positive data on aducanumab in Alzheimer's. Medscape. Available at http://www.medscape.com/viewarticle/844502 [accessed May 11, 2015].
42. Jennings G. T., and, Bachmann M. F., (2008) The coming of age of virus-like particles vaccines. Biol. Chem. 389, 521-536.
43. Kafi K., Betting D. J., Yamada R. E., Bacica M., Kristopher K., Steward K. K., John M., and, Timmerman J. M., (2009) Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol. Immunol. 46, 448-456.
44. Kaliyaperumal A., Chauhan V. S., Talwar G. P., and, Raghupathy R., (1995) Carrier-induced epitope-specific regulation and its bypass in a protein-protein conjugate. Eur. J. Immunol. 25, 3375-3380.
45. Karran E., and, Hardy J., (2014) A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer's disease. Ann. Neurol. 76, 185-205.
46. Keller D. M., (2015) Finally, a big win for a monoclonal in Alzheimer's. Medscape. http://www.medscape.com/viewarticle/841856 [accessed March 23, 2015].
47. Kensil C. R., (2006) Immunomodulatory adjuvants from Quillaja saponaria, in Immunopotentiators in Modern Vaccines (, Schijns V. E., and, O'Hagan D. T., eds), pp. 109-122. Academic Press, Burlington.
48. Kokjohn T., and, Roher A. E., (2009) Antibody responses, amyloid-β peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol. Disord. Drug Targets 8, 88-97.
49. Kontsekova E., Zilka N., Kovacech B., Novak P., and, Novak M., (2014) First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerization and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res. Ther. 6, 44. doi: 10.1186/alzrt278. eCollection 2014.
50. Lambracht-Washington D., and, Rosenberg R. N., (2012) Active DNA Aβ42 vaccination as immunotherapy for Alzheimer's disease. Transl. Neurosci. 3, 307-313.
51. Lambracht-Washington D., and, Rosenberg R. N., (2015) A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients. Neurobiol. Aging 36, 1274-1281. doi: 10.1016/j.neurobiolaging.2014.12.011.
52. Larson M. E., and, Lesné S. E., (2012) Soluble Aβ oligomer production and toxicity. J. Neurochem. 120 (Suppl. 1), 125-139.
53. Lasagna-Reeves C. A., Castillo-Carranza D. L., Sengupta U., Troncoso J., Jackson G. R., and, Kayed R., (2012) Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 26, 1946-1959.
54. Lee M., Bard F., Johnson-Wood K., Lee C., Hu K., Griffith S. G., Black R. S., Schenk D., and, Seubert P., (2005) Abeta 42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol. 58, 430-435.
55. Li W., Joshi M. D., Singhania S., Ramsey K. H., and, Murthy A. K., (2014) Peptide vaccine: progress and challenges. Vaccines 2, 515-536. doi: 10.3390/vaccines2030515.
56. Liu Y. H., Bu X. L., Liang C. R., et al,. (2015a) An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. J. Neuroinflammation 12, 153. doi: 10.1186/s12974-015-0379-4.
57. Liu S., Shi D. Y., Wang H. C., Yu Y. Z., Xu Q., and, Sun Z. W., (2015b) Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice. Sci. Rep. 5, 7771. doi: 10.1038/srep07771.
58. Loukov D., Naidoo A., and, Bowdish D. M. E., (2015) Immunosenescence: implications for vaccination programs in the elderly. Vaccin. Dev. Ther. 5, 17-29.
59. 1-11 antibody binds to different b-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem. 282, 22376-22386.
60. Mandler M., Santic R., Gruber P., Cinar Y., Pichler D., Funke S. A., Willbold D., Schneeberger A., Schmidt W., and, Mattner F., (2015) Tailoring the antibody response to aggregated Aβ using novel Alzheimer-vaccines. PLoS ONE 10, e0115237. doi: 10.1371/journal.pone.0115237.
61. Marciani D. J., (2003) Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today 8, 934-945.
62. Marciani D. J., (2014) New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies. Drug Discov. Today 19, 912-920.
63. Marciani D. J., (2015a) Is fucose the answer to the immunomodulatory paradox of Quillaja saponins? Int. Immunopharmacol. 29, 908-913. doi: 10.1016/j.intimp.2015.10.028.
64. Marciani D. J., (2015b) Alzheimer's disease vaccine development: a new strategy focusing on immune modulation. J. Neuroimmunol. 287, 54-63.
65. Marciani D. J., (2015c) Alzheimer's disease: toward the rational design of an effective vaccine. Rev. Neuropsiquiatr. 78, 140-152.
66. Marciani D. J., Kensil C. R., Beltz G. A., Hung C. H., Cronier J., and, Aubert A., (1991) Genetically-engineered subunit vaccine against feline leukemia virus: protective immune response in cats. Vaccine 9, 89-96.
67. Marciani D. J., Pathak A. K., Reynolds R. G., Seitz L., and, May R., (2001) Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int. Immunopharmacol. 1, 813-818.
68. Martorana A., Bulati M., Buffa S., Pellicano M., Caruso C., Candore G., and, Colonna-Romano G., (2012) Immunosenescence, inflammation and Alzheimer's disease. Longev. Healthspan 1, 8. doi: 10.1186/2046-2395-1-8. eCollection 2012.
69. Matsumoto Y., Niimi N., and, Kohyama K., (2013) Development of a new DNA vaccine for Alzheimer's disease targeting a wide range of Aβ species and amlyloidogenic peptides. PLoS ONE 8, e75203. doi: 10.1371/journal.pone.0075203.
70. Mazzola P., Radhi S., Mirandola L., Annoni G., Jenkins M., Cobos E., and, Chiriva-Internati M., (2012) Aging, cancer and cancer vaccines. Immun. Ageing 9, 4. doi: 10.1186/1742-4933-9-4.
71. Mengel D., Röskam S., Neff F., Balakrishnan K., Deuster O., Gold M., Oertel W. H., Bacher M., Bach J.-P., and, Dodel R., (2013) Naturally occurring autoantibodies interfere with β-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment. Transl. Psychiatry 3, e236. doi: 10.1038/tp.2012.151.
72. Merlini G., and, Belloti V., (2003) Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349, 583-596.
73. 1-42. 2013. J. Alzheimers Dis. 34, 133-137.
74. Mucke L., and, Selkoe D. J., (2012) Neurotoxicity of amyloid β-protein: synaptic and network disfunction. Cold Spring Harb. Perspect Med. 2, a006338. doi: 10.1101/cshperspect.a006338
75. Ono K., and, Yamada M., (2011) Low-n oligomers as therapeutic targets of Alzheimer's disease. J. Neurochem. 117, 19-28.
76. O'Nuallain B., Williams A. D., McWilliams-Koeppen H. P., Acero L., Weber A., Ehrlich H., Schwarz H. P., and, Solomon A., (2010) Anti-amyloidogenic activity in IgGs contained in normal plasma. J. Clin. Immunol. 30 (Suppl 1), S37-S42.
77. Parmiani G., Russo V., Maccalli C., Parolini D., Rizzo N., and, Maio M., (2014) Peptide-based vaccines for cancer therapy. Hum. Vaccin. Immunother. 10, 3175-3178.
78. Patton R. L., Kalback W. M., Esh C. L., et al,. (2006) Amyloid-β peptide remnants in AN-1792-immunized Alzheimer's disease patients. A biochemical analysis. Am. J. Pathol. 169, 1048-1063.
79. Pedersen J. T., and, Sigurdsson E. M., (2015) Tau immunotherapy for Alzheimer's disease. Trends Mol. Med. 21, 394-402.
80. Pedersen N. C., Johnson L., Birch D., and, Theilen G. H., (1986) Possible immunoenhancement of persistent viremia by feline leukemia virus glycoprotein vaccines in challenge-exposure situations where whole inactivated virus were protective. Vet. Immunol. Immunopathol. 11, 123-148.
81. Perez-Garmendia R., and, Gevorkian G., (2013) Pyroglutamate-modified amyloid beta peptides: emerging targets for Alzheimer's disease immunotherapy. Curr. Neuropharmacol. 11, 491-498.
82. Perlmann P., and, Hammarström S., (1985) Antigen-antibody reactions, in Immunology (, Hanson L. Å., and, Wigzell H., eds), pp. 41-56. Butteworths, London.
83. Phay M., Welzel A. T., Williams A. D., McWilliams-Koeppen H. P., Blinder V., O'Malley T. T., Solomon A., Walsh D. M., and, O'Nuallain B., (2015) IgG conformer's binding to amyloidogenic aggregates. PLoS ONE 10, e0137344. doi: 10.1371/journal.pone.0137344.
84. Pillot T., Goethals M., Vanloo B., Talussot C., Brasseuri R., Vandekerckhove J., Rosseneu M., and, Linsi L., (1996) Fusogenic properties of the C-terminal domain of the Alzheimer's β-amyloid peptide. J. Biol. Chem. 271, 28757-28765.
85. Raghavendra V., Tanga F. Y., and, DeLeo J. A., (2004) Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur. J. Neurosci. 20, 467-473.
86. Rasool S., Albay R. III, Martinez-Coria H., et al,. (2012) Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice. Mol. Neurodegener. 7, 37. doi: 10.1186/1750-1326-7-37.
87. Rizzi L., Rosset I., and, Roriz-Cruz M., (2014) Global epidemiology of dementia: Alzheimer's and vascular types. Biomed. Res. Int. 2014, 908915. doi: 10.1155/2014/908915.
88. + T cells do not trigger autoimmune neuroinflammation in a murine model of Alzheimer's disease. J. Neuroinflammation 12, 95. doi: 10.1186/s12974-015-0317-5.
89. Roychaudhuri R., Yang M., Hoshi M. M., and, Teplow D. B., (2009) Amyolid-β protein assembly and Alzheimer disease. J. Biol. Chem. 284, 4749-4753.
90. Rozenstein-Tsalkovich L., Grigoriadis N., Lourbopoulos A., Nousiopoulou E., Kassis I., Abramsky O., Karussis D., and, Rosenmann H., (2013) Reported immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp. Neurol. 248, 451-456.
91. Ryan D. A., Narrow W. C., Federoff H. J., and, Bowers W. J., (2010) An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. J. Neurosci. Methods 190, 171-179.
92. Saade F., and, Petrovsky N., (2012) Technologies for enhanced efficacy of DNA vaccines. Expert Rev. Vaccines 11, 189-209. doi: 10.1586/erv.11.188.
93. Sad S., Malini Gupta H., Talwar G. P., and, Raghupathy R., (1991) Carrier-induced suppression of the antibody response to a 'self' hapten. Immunology 74, 223-227.
94. Sad S., Rao K., Arora R., Talwar G. P., and, Raghupathy R., (1992) Bypass of carrier-induced epitope-specific suppression using a T-helper epitope. Immunology 76, 599-603.
95. Sandberg A., Luheshi L. M., Söllvander S., et al,. (2010) Stabilization of neurotoxic Alzheimer amyloid-β oligomers by protein engineering. Proc. Natl Acad. Sci. USA 107, 15595-15600.
96. Schenk D., Barbour R., Dunn W., et al,. (1999) Immunization with amyloid-b attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
97. Schindowski C., Zimmermann J., and, Schindowski K., (2014) Intravenous immunoglobulin for the treatment of Alzhemer's disease: current evidence and considerations. Degen. Neurol. Neuromusc. Dis. 4, P121-P130.
98. Schneeberger A., Mandler M., Otawa O., Zauner W., Mattner F., and, Schmidt W., (2009) Development of AFFITOPE vaccines for Alzheimer's disease-from concept to clinical testing. J. Nutr. Health Aging 13, 264-267.
99. Schutze M. P., Leclerc C., Jolivet M., Audibert F., and, Chedid L., (1985) Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J. Immunol. 135, 2319-2322.
100. Sun H. X., Xie Y., and, Ye Y. P., (2009) ISCOMs and ISCOMATRIX. Vaccine 27, 4388-4401.
101. Thomas P. G., and, Harn D. A., (2004) Immune biasing by helminth glycans. Cell. Microbiol. 6, 13-22.
102. Toyama B. H., and, Weissman J. S., (2011) Amyloid structure: conformational diversity and consequences. Annu. Rev. Biochem. 80, 557-585.
103. Trinchieri G., and, Sher A., (2007) Cooperation of Toll-like receptor signal in innate immune defense. Nat. Rev. Immunol. 7, 179-190.
104. Tundup S., Srivastava L., and, Harn D. A., Jr, (2012) Polarization of host immune responses by helminth-expressed glycans. Ann. NY Acad. Sci. 1253, E1-E13.
105. Vallejos A. N., Bryl E., Klarskov K., Naylor S., Weyand C. M., and, Goronzy J. J., (2002) Molecular basis for the loss of CD28 expression in senescent T cells. J. Biol. Chem. 49, 46940-46949.
106. Vasilevko V., Pop V., Kim H. J., Saing T., Glabe C. C., Milton S., Barrett E. G., Cotman C. W., Cribbs D. H., and, Head E., (2010) Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol. Dis. 39, 301-310.
107. Vollmar P., Kullmann J. S., Thilo B., Claussen M. C., Rothhammer V., Jacobi H., Sellner J., Nessler S., Korn T., and, Hemmer B., (2010) Active immunization with amyloid-b 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system. J. Immunol. 185, 6338-6347.
108. Wang S., Yu Y., Geng S., et al,. (2014) A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model. Alzheimers Res. Ther. 6, 26. doi: 10.1186/alzrt256. eCollection 2014.
109. Weinberger B., Herndler-Brandstetter D., Schwanninger A., Weiskopf D., and, Grubeck-Loebenstein B., (2008) Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis. 46, 1078-1084. doi: 10.1086/529197.
110. Welzel A. T., Williams A. D., McWilliams-Koeppen H. P., et al,. (2012) Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide. PLoS ONE 7, e50317. doi: 10.1371/journal.pone.0050317.
111. Winblad B., Graf A., Riviere M. E., Andreasen N., and, Ryan J. M., (2014) Active immunotherapy options for Alzheimer's disease. Alzheimers Res. Ther. 6, 7. doi: 10.1186/alzrt237. eCollection 2014.
112. Wisniewski T., and, Goni F., (2014) Immunotherapy for Alzheimer's disease. Biochem. Pharmacol. 88, 499-507.
113. Wisniewski T., and, Konietzko U., (2008) Amyloid-β immunization for Alzheimer's disease. Lancet Neurol. 7, 805-811.
114. Wu C., Murray M. M., Bernstein S. L., Condron M. M., Bitan G., Shea J.-E., and, Bowers M. T., (2009) The structure of Aβ42 C-terminal fragments probed by a combined experimental and theoretical study. J. Mol. Biol. 387, 492-501.
115. 42 immunization. Brain 136, 2677-2696.